[{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"3d373e1f-fe2b-41f0-84e9-9ccc47be3cca","acronym":"Pangeia-2","url":"https://clinicaltrials.gov/study/NCT06417801","created_at":"2024-05-18T04:15:22.395Z","updated_at":"2025-02-25T15:14:39.218Z","phase":"","brief_title":"Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.","source_id_and_acronym":"NCT06417801 - Pangeia-2","lead_sponsor":"AstraZeneca","biomarkers":" ER","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/17/2024","start_date":" 06/17/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-13"},{"id":"155f3329-d4dc-4e2c-bac9-4feb6555c97c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05659797","created_at":"2022-12-21T14:58:43.479Z","updated_at":"2025-02-25T15:20:11.117Z","phase":"Phase 1","brief_title":"FES BPET-DBT in Newly Diagnosed Breast Cancer","source_id_and_acronym":"NCT05659797","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-11"},{"id":"a22b0db3-f6b3-489e-b362-7e9a7131a6f7","acronym":"ELECTRA","url":"https://clinicaltrials.gov/study/NCT05386108","created_at":"2022-05-23T15:53:51.405Z","updated_at":"2025-02-25T15:27:22.960Z","phase":"Phase 1/2","brief_title":"Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer","source_id_and_acronym":"NCT05386108 - ELECTRA","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"996991a4-16ed-4414-90f1-2f630a1b4a1d","acronym":"lidERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04961996","created_at":"2021-07-14T14:53:31.141Z","updated_at":"2025-02-25T15:35:10.567Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","source_id_and_acronym":"NCT04961996 - lidERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 4200","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 11/21/2033","study_completion_date":" 11/21/2033","last_update_posted":"2025-02-10"},{"id":"96089508-6422-493f-82c5-12ed65ed1d61","acronym":"ELCIN","url":"https://clinicaltrials.gov/study/NCT05596409","created_at":"2022-10-27T15:58:31.639Z","updated_at":"2025-02-25T16:33:10.407Z","phase":"Phase 2","brief_title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","source_id_and_acronym":"NCT05596409 - ELCIN","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-07"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"432f1e5f-02a6-4552-b299-64f4b470c25a","acronym":"heredERA","url":"https://clinicaltrials.gov/study/NCT05296798","created_at":"2022-04-20T16:53:29.043Z","updated_at":"2025-02-25T12:28:43.790Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","source_id_and_acronym":"NCT05296798 - heredERA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (RG6171) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 922","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-04"},{"id":"55cb45be-28da-426b-95b0-c684a21c9966","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311933","created_at":"2021-01-18T10:56:52.952Z","updated_at":"2025-02-25T16:58:44.113Z","phase":"Phase 2","brief_title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02311933","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • NCOA3","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["ER • NCOA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/28/2015","start_date":" 05/28/2015","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 02/04/2025","study_completion_date":" 02/04/2025","last_update_posted":"2025-02-03"},{"id":"1bc0890a-1931-45f9-86be-541afa2f8663","acronym":"","url":"https://clinicaltrials.gov/study/NCT02778685","created_at":"2021-01-18T13:37:54.643Z","updated_at":"2025-02-25T17:35:45.267Z","phase":"Phase 2","brief_title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT02778685","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ibrance (palbociclib) • fulvestrant • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2025-01-29"},{"id":"1fa5498c-1aea-4d87-9474-f28a1ded3063","acronym":"MANTA","url":"https://clinicaltrials.gov/study/NCT02216786","created_at":"2021-01-18T10:23:25.940Z","updated_at":"2025-02-25T15:06:06.929Z","phase":"Phase 2","brief_title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","source_id_and_acronym":"NCT02216786 - MANTA","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 01/16/2014","start_date":" 01/16/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2024-12-02"},{"id":"5fd012c6-ecde-4163-8dec-e89ec5177b6b","acronym":"PRESTO","url":"https://clinicaltrials.gov/study/NCT02238808","created_at":"2021-01-18T10:30:15.448Z","updated_at":"2024-07-02T16:34:25.821Z","phase":"Phase 2","brief_title":"A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers","source_id_and_acronym":"NCT02238808 - PRESTO","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 07/30/2018","primary_completion_date":" 07/30/2018","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-06-14"},{"id":"bc4bd5fe-eb27-4217-b824-f4e3646427cd","acronym":"UPCC 02112","url":"https://clinicaltrials.gov/study/NCT01594216","created_at":"2021-01-18T06:48:41.179Z","updated_at":"2024-07-02T16:34:26.790Z","phase":"Phase 2","brief_title":"Ruxolitinib in Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT01594216 - UPCC 02112","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/09/2016","study_completion_date":" 04/09/2016","last_update_posted":"2024-06-12"},{"id":"7b8dfa1c-2da2-4d1b-8945-ea6ec1ea6662","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720260","created_at":"2023-02-09T15:00:11.511Z","updated_at":"2024-07-02T16:34:27.630Z","phase":"Phase 2","brief_title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","source_id_and_acronym":"NCT05720260","lead_sponsor":"National Taiwan University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • fulvestrant • Truqap (capivasertib) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"3664f3ff-fa68-4517-8986-00649bcc87de","acronym":"VERITAC-3","url":"https://clinicaltrials.gov/study/NCT05909397","created_at":"2023-06-18T17:07:52.437Z","updated_at":"2024-07-02T16:34:37.580Z","phase":"Phase 3","brief_title":"A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer","source_id_and_acronym":"NCT05909397 - VERITAC-3","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1180","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 07/26/2030","study_completion_date":" 07/26/2030","last_update_posted":"2024-06-06"},{"id":"469f79f5-7bed-470f-bde8-dd6a3a9d7203","acronym":"GO39932","url":"https://clinicaltrials.gov/study/NCT03332797","created_at":"2021-01-17T18:03:30.772Z","updated_at":"2024-07-02T16:34:37.744Z","phase":"Phase 1","brief_title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT03332797 - GO39932","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-06"},{"id":"5cc7ea58-5792-4936-b0c7-76d10e021a5b","acronym":"PASTOR","url":"https://clinicaltrials.gov/study/NCT02599714","created_at":"2021-01-18T12:37:17.664Z","updated_at":"2024-07-02T16:34:37.661Z","phase":"Phase 1","brief_title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","source_id_and_acronym":"NCT02599714 - PASTOR","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 12/07/2015","start_date":" 12/07/2015","primary_txt":" Primary completion: 03/30/2018","primary_completion_date":" 03/30/2018","study_txt":" Completion: 11/23/2023","study_completion_date":" 11/23/2023","last_update_posted":"2024-06-06"},{"id":"4097b476-e251-40e9-8dd4-e80b740ce49e","acronym":"NCI-2018-01189","url":"https://clinicaltrials.gov/study/NCT03132467","created_at":"2021-01-18T15:26:00.796Z","updated_at":"2024-07-02T16:34:38.153Z","phase":"Phase 1","brief_title":"Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer","source_id_and_acronym":"NCT03132467 - NCI-2018-01189","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 05/20/2024","study_completion_date":" 05/20/2024","last_update_posted":"2024-06-05"},{"id":"7d23d816-d6f4-41e9-9cb9-d2526c0cc2b3","acronym":"OPERA-01","url":"https://clinicaltrials.gov/study/NCT06016738","created_at":"2023-08-30T14:08:41.909Z","updated_at":"2024-07-02T16:34:59.724Z","phase":"Phase 3","brief_title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06016738 - OPERA-01","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-31"},{"id":"804b3bfa-25bb-48de-b7d7-0fa059994b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT05181033","created_at":"2022-01-06T22:53:35.462Z","updated_at":"2025-02-25T13:36:03.686Z","phase":"Phase 2","brief_title":"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor","source_id_and_acronym":"NCT05181033","lead_sponsor":"National University Hospital, Singapore","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • fulvestrant • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-17"},{"id":"994eeea2-7a4a-4a36-a0cd-257f621bb02b","acronym":"ASTER 70s","url":"https://clinicaltrials.gov/study/NCT01564056","created_at":"2021-01-18T06:37:45.771Z","updated_at":"2024-07-02T16:35:02.925Z","phase":"Phase 3","brief_title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","source_id_and_acronym":"NCT01564056 - ASTER 70s","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1989","initiation":"Initiation: 04/12/2012","start_date":" 04/12/2012","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-05-17"},{"id":"24e8ae9d-33b8-4686-b35a-14011c3c0cf0","acronym":"NAOMI","url":"https://clinicaltrials.gov/study/NCT04568616","created_at":"2021-01-18T21:49:14.275Z","updated_at":"2024-07-02T16:35:03.439Z","phase":"Phase 2","brief_title":"Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)","source_id_and_acronym":"NCT04568616 - NAOMI","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-15"},{"id":"36f83181-4b5b-4669-bdd8-2e98f591e4f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03719495","created_at":"2021-01-18T18:13:48.487Z","updated_at":"2024-07-02T16:35:03.604Z","phase":"","brief_title":"Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer","source_id_and_acronym":"NCT03719495","lead_sponsor":"Duke University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 06/19/2019","start_date":" 06/19/2019","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2024-05-15"},{"id":"5a4a7ea1-f6f6-41ac-a252-4ee9ed1147d3","acronym":"FINER","url":"https://clinicaltrials.gov/study/NCT04650581","created_at":"2021-01-19T20:40:12.739Z","updated_at":"2024-07-02T16:35:04.541Z","phase":"Phase 3","brief_title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","source_id_and_acronym":"NCT04650581 - FINER","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-09"}]